William Wegener, MD, PhD
Gilead Sciences
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name William Wegener, MD, PhD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 13:24 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT01956812 · Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic CancerGilead Sciences · terminated · Metastatic Pancreatic Cancer, Pancreatic Cancer · study chair
- Ph1NCT01728207 · Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLLGilead Sciences · terminated · Non-hodgkin's Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma · study chair
- Ph1NCT01663766 · Phase I Study of Milatuzumab for Graft Versus Host DiseaseGilead Sciences · terminated · GVHD (Acute or Chronic), Acute Myeloid or Lymphoblastic Leukemia (AML or ALL), Myelodysplastic Syndrome · study chair
- Ph1/Ph2NCT01101581 · Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHLGilead Sciences · withdrawn · Non Hodgkin's Lymphoma, NHL, Aggressive NHL · study chair
- Ph1/Ph2NCT00603668 · Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLLGilead Sciences · completed · Chronic Lymphocytic Lymphoma · study chair
- Ph1/Ph2NCT00603863 · Safety and Efficacy Study of Different Doses of 90Y-hPAM4 Combined With Gemcitabine in Pancreatic CancerGilead Sciences · completed · Pancreatic Cancer · study chair
- Ph1/Ph2NCT00596804 · Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's LymphomaGilead Sciences · completed · Non-Hodgkin's Lymphoma, Lymphoma, Diffuse, Lymphoma, Diffuse, Mixed Lymphocytic-Histiocytic · study chair
- Ph1/Ph2NCT00597129 · Safety and Efficacy Study of 90Y-hPAM4 at Different DosesGilead Sciences · completed · Pancreatic Cancer · study chair
- Ph1/Ph2NCT00546793 · Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLLGilead Sciences · completed · NHL, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell · study director
- Ph1/Ph2NCT00547066 · Study of Veltuzumab (hA20) at Different Doses in Patients With ITPGilead Sciences · terminated · Purpura, Thrombocytopenic, Idiopathic, Autoimmune Thrombocytopenic Purpura, Purpura, Thrombocytopenic, Autoimmune · study chair
- Ph1/Ph2NCT00421525 · Phase I/II Study of hLL1 in Multiple MyelomaGilead Sciences · completed · Multiple Myeloma, Myeloma, Plasma-Cell, PLASMACYTOMA · study chair
- Ph1/Ph2NCT00285428 · Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's LymphomaGilead Sciences · completed · Non-Hodgkin's Lymphoma · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 13:24 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in childhood acute lymphoblastic leukemia.